Press Release: Tarveda : Tarveda Therapeutics to Present Data from Phase 2 Study of PEN-221 at 2021 ASCO Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics will present data from its Phase 2 clinical trial of PEN-221 at the 2021 ASCO Annual Meeting occurring virtually June 4-8, 2021.
Read full article »
Tarveda is a biopharmaceutical company that discovers and develops miniaturized drug conjugates for the treatment of solid tumor malignancies.
Read more